专题12 环球时报：中国自主知识产权的“人造肺”上市-2023年高考英语外刊阅读及模拟强化训练

China's 'artificial lung' with independent intellectual property rights comes on market 中国自主知识产权的“人造肺”上市 文章选自《环球时报》 主题语境：人与社会 子语境：科技发明 原文出处：Global Times 语篇类型：说明文 关键词：lung；machine；product；hospital 篇章导读：中国航天科技集团公司和北京协和医院周三联合宣布，他们拥有完全自主知识产权的新型“人工肺”已在北京上市。 原汁原味外刊阅读及模拟强化训练 China Aerospace Science and Technology Corporation and Peking Union Medical College Hospital jointly announced on Wednesday that their new "artificial lung" with fully independent intellectual property rights has come onto the market in Beijing. Their ECMO (extracorporeal membrane oxygenation) system is also commonly known as an "artificial lung." The ECMO machine is similar to a heart-lung bypass machine used in open-heart surgery. It pumps and oxygenates a patient's blood from outside the body, allowing the heart and lungs to rest. The whole machine, called Huisheng-I ECMO, weighs about 7.5 kilograms, less than half the weight of similar foreign products, so it can better meet the emergency and transport needs of critically ill patients. ECMO is an important part of life support for patients, as well as an important treatment means to gain time for them. However, the technical threshold is high, as is the price, and the key core technologies have previously been monopolized by a few multinational medical device enterprises. The development of China's ECMO system has broken the monopoly of foreign enterprises, improved the access to advanced life support equipment in China, and significantly reduced the price of the product, which is conducive to reducing the burden of medical treatment for patients. "The technology of the product is independent and controllable, with completely independent intellectual property rights," Zeng Si, the director of the ECMO research project, said on Wednesday. "The overall performance and indicators reach the level of similar international products; some indicators are even better than similar products," Zeng noted.